Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 10/2015

01.10.2015 | Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Abnormalities of the Exocrine Pancreas in Type 1 Diabetes

verfasst von: Martha Campbell-Thompson, Teresa Rodriguez-Calvo, Manuela Battaglia

Erschienen in: Current Diabetes Reports | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Type 1 diabetes (T1D) is considered a pancreatic beta cell-specific disease that results in absolute insulin deficiency. Nevertheless, clinical studies from 1940 onwards showed that patients with T1D had an abnormal exocrine pancreas due to the presence of subclinical exocrine insufficiency and acinar atrophy. Exocrine abnormalities are an important, and mostly neglected, characteristic associated with T1D. It is however still unclear whether the exocrine dysfunction in T1D is a primary damage caused by the same pathogenic event that led to beta cell destruction or secondary to beta cell loss. In this review, we collect evidence supporting the hypothesis that T1D is a combined endocrine-exocrine disease in which the loss of functional beta cell mass is most clinically apparent.
Literatur
1.
Gale EAM. Epidemiology of type 1 diabetes [internet]. Diapedia. 2014 Aug 13;2104085168 rev. no. 39.
2.
Pollard HM, Miller L, Brewer WA. The external secretion of the pancreas and diabetes mellitus. Am J Dig Dis. 1943;10(1):20–3.CrossRef
3.
Perczak-Dudkowska B, Niewiedziol B. Exocrine function of the pancreas in juvenile onset diabetes mellitus. I. pH, duodenal content volume and bicarbonate concentration and secretion. Pediatr Pol. 1984;59(8):605–12.PubMed
4.•
Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619–33. The first report of decreased pancreatic size in patients with T1D. PubMedCrossRef
5.
Williams AJ, Thrower SL, Sequeiros IM, Ward A, Bickerton AS, Triay JM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2012;97(11):E2109–13.PubMedCrossRef
6.
Tan GD. The pancreas. Anaesth Intensive Care Med. 2008;9(10):424–7.CrossRef
7.
8.
9.
Eberhard D, Lammert E. The pancreatic beta-cell in the islet and organ community. Curr Opin Genet Dev. 2009;19(5):469–75.PubMedCrossRef
10.
11.
Pandol SJ. The exocrine pancreas. Colloquium series on integrated systems physiology: from molecule to function to disease. San Rafael (CA) 2010.
12.
Piciucchi M, Capurso G, Archibugi L, Delle Fave MM, Capasso M, Delle FG. Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment. Int J Endocrinol. 2015;2015:595649.PubMedCentralPubMedCrossRef
13.
Henderson JR, Daniel PM, Fraser PA. The pancreas as a single organ: the influence of the endocrine upon the exocrine part of the gland. Gut. 1981;22(2):158–67.PubMedCentralPubMedCrossRef
14.
15.
Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. Pancreas. 1996;13(4):356–71.PubMedCrossRef
16.
Di Sebastiano P, di Mola FF, Bockman DE, Friess H, Buchler MW. Chronic pancreatitis: the perspective of pain generation by neuroimmune interaction. Gut. 2003;52(6):907–11.PubMedCentralPubMedCrossRef
17.
Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet. 2015.
18.
Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338–42.PubMedCrossRef
19.
Ewald NH, P.D. Alterations in exocrine pancreatic function in diabetes mellitus. The Pancreapedia. 2015;version 1.0.
20.
Vacca JB, Henke WJ, Knight Jr WA. The exocrine pancreas in diabetes mellitus. Ann Intern Med. 1964;61:242–7.PubMedCrossRef
21.
Lankisch PG, Manthey G, Otto J, Koop H, Talaulicar M, Willms B, et al. Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion. 1982;25(3):211–6.PubMedCrossRef
22.
Semakula C, Vandewalle CL, Van Schravendijk CF, Sodoyez JC, Schuit FC, Foriers A, et al. Abnormal circulating pancreatic enzyme activities in more than twenty-five percent of recent-onset insulin-dependent diabetic patients: association of hyperlipasemia with high-titer islet cell antibodies. Belgian Diabetes Registry. Pancreas. 1996;12(4):321–33.PubMedCrossRef
23.
Hardt PD, Krauss A, Bretz L, Porsch-Ozcurumez M, Schnell-Kretschmer H, Maser E, et al. Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetol. 2000;37(3):105–10.PubMedCrossRef
24.
Hardt PD, Hauenschild A, Nalop J, Marzeion AM, Jaeger C, Teichmann J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatol : Off J Int Assoc Pancreatol. 2003;3(5):395–402.CrossRef
25.
Larger E, Philippe MF, Barbot-Trystram L, Radu A, Rotariu M, Nobecourt E, et al. Pancreatic exocrine function in patients with diabetes. Diabet Med : J Br Diabet Assoc. 2012;29(8):1047–54.CrossRef
26.
Dominguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol. 1995;90(10):1834–7.PubMed
27.
28.
Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD. Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations (FEC) in patients with diabetes mellitus. Eur J Med Res. 2009;14(3):118–22.PubMedCentralPubMed
29.
Bilgin M, Balci NC, Momtahen AJ, Bilgin Y, Klor HU, Rau WS. MRI and MRCP findings of the pancreas in patients with diabetes mellitus: compared analysis with pancreatic exocrine function determined by fecal elastase 1. J Clin Gastroenterol. 2009;43(2):165–70.PubMedCrossRef
30.
Grippo PJ, Venkatasubramanian PN, Knop RH, Heiferman DM, Iordanescu G, Melstrom LG, et al. Visualization of mouse pancreas architecture using MR microscopy. Am J Pathol. 2011;179(2):610–8.PubMedCentralPubMedCrossRef
31.
Sequeiros IM, Hester K, Callaway M, Williams A, Garland Z, Powell T, et al. MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients. Br J Radiol. 2010;83(995):921–6.PubMedCentralPubMedCrossRef
32.••
Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308(22):2337–9. The first demonstration in humans that pancreas weight is reduced in individuals at risk of developing T1D, thus suggesting that early atrophy of the organ may be an important sub-clinical feature of T1D pathogenesis.PubMedCrossRef
33.
Di Gialleonardo V, de Vries EF, Di Girolamo M, Quintero AM, Dierckx RA, Signore A. Imaging of β-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev. 2012.
34.
35.
MacLean N, Ogilvie RF. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes. 1955;4(5):367–76.PubMedCrossRef
36.
Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia. 1983;24(5):366–71.PubMedCrossRef
37.
Foulis AK, Stewart JA. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia. 1984;26(6):456–61.PubMedCrossRef
38.
Altobelli E, Blasetti A, Verrotti A, Di Giandomenico V, Bonomo L, Chiarelli F. Size of pancreas in children and adolescents with type I (insulin-dependent) diabetes. J Clin Ultrasound. 1998;26(8):391–5.PubMedCrossRef
39.
Fonseca V, Berger LA, Beckett AG, Dandona P. Size of pancreas in diabetes mellitus: a study based on ultrasound. Br Med J (Clin Res Ed). 1985;291(6504):1240–1.CrossRef
40.
Gilbeau JP, Poncelet V, Libon E, Derue G, Heller FR. The density, contour, and thickness of the pancreas in diabetics: CT findings in 57 patients. AJR Am J Roentgenol. 1992;159(3):527–31.PubMedCrossRef
41.
Goda K, Sasaki E, Nagata K, Fukai M, Ohsawa N, Hahafusa T. Pancreatic volume in type 1 and type 2 diabetes mellitus. Acta Diabetol. 2001;38(3):145–9.PubMedCrossRef
42.
Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011;121(1):442–5.PubMedCentralPubMedCrossRef
43.
Löhr M, Klöppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia. 1987;30(10):757–62.PubMedCrossRef
44.
Muniraj T, Aslanian HR, Farrell J, Jamidar PA. Chronic pancreatitis, a comprehensive review and update. Part I: epidemiology, etiology, risk factors, genetics, pathophysiology, and clinical features. Dis Mon : DM. 2014;60(12):530–50.PubMedCrossRef
45.
Beger HG, Buchler M, Kozarek R, Lerch M, Neoptolemos JP, Warshaw A, et al. The pancreas: an integrated textbook of basic science, medicine, and surgery: Wiley; 2 edition; 2008. p. 1024.
46.
Comfort MW, Gambill EE, Baggenstoss AH. Chronic relapsing pancreatitis; a study of 29 cases without associated disease of the biliary or gastrointestinal tract. Gastroenterology. 1946;6:376–408.PubMed
47.
Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986;29(5):267–74.PubMedCrossRef
48.••
Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes. 2014;63(11):3880–90. The first demonstration that immune infiltrates in the pancreas of patients with T1D occurs also in the exocrine area. PubMedCrossRef
49.
Willcox A, Richardson S, Bone A, Foulis A, Morgan N. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155(2):173–81.PubMedCentralPubMedCrossRef
50.
Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209(1):51–60.PubMedCentralPubMedCrossRef
51.••
Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes. 2013;62(6):2072–7. The first demonstration that neutrophils accumulate in the pancreas of patients with T1D especially in the exocrine area. PubMedCentralPubMedCrossRef
52.
Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren O. On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol. 2012;181(5):1735–48.PubMedCentralPubMedCrossRef
53.
Kloppel G. Islet histopathology in diabetes mellitus. Kloppel G, Heitz P, editors. Edinburgh: Churchill Livingstone; 1984. 239 p.
54.
Panicot L, Mas E, Thivolet C, Lombardo D. Circulating antibodies against an exocrine pancreatic enzyme in type 1 diabetes. Diabetes. 1999;48(12):2316–23.PubMedCrossRef
55.
Endo T, Takizawa S, Tanaka S, Takahashi M, Fujii H, Kamisawa T, et al. Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. Diabetes. 2009;58(3):732–7.PubMedCentralPubMedCrossRef
56.
Taniguchi T, Okazaki K, Okamoto M, Seko S, Tanaka J, Uchida K, et al. High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. Pancreas. 2003;27(1):26–30.PubMedCrossRef
57.
Kobayashi T, Nakanishi K, Kajio H, Morinaga S, Sugimoto T, Murase T, et al. Pancreatic cytokeratin: an antigen of pancreatic exocrine cell autoantibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33(6):363–70.PubMedCrossRef
58.
di Cesare E, Previti M, Lombardo F, Mazzù N, di Benedetto A, Cucinotta D. Prevalence of autoantibodies to carbonic anhydrase II and lactoferrin in patients with type 1 diabetes. Ann N Y Acad Sci. 2004;1037:131–2.PubMedCrossRef
59.
Hardt PD, Ewald N, Bröckling K, Tanaka S, Endo T, Kloer HU, et al. Distinct autoantibodies against exocrine pancreatic antigens in European patients with type 1 diabetes mellitus and non-alcoholic chronic pancreatitis. JOP. 2008;9(6):683–9.PubMed
60.
Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M, et al. Increased complement activation in human type 1 diabetes pancreata. Diabetes Care. 2013;36(11):3815–7.PubMedCentralPubMedCrossRef
Metadaten
Titel
Abnormalities of the Exocrine Pancreas in Type 1 Diabetes
verfasst von
Martha Campbell-Thompson
Teresa Rodriguez-Calvo
Manuela Battaglia
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 10/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0653-y

Weitere Artikel der Ausgabe 10/2015

Current Diabetes Reports 10/2015 Zur Ausgabe

Immunology and Transplantation (A Pileggi, Section Editor)

Pediatric Autologous Islet Transplantation

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes

Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Vascular Smooth Muscle as a Target for Novel Therapeutics

Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patient—An Evidence-based Approach

Lifestyle Management to Reduce Diabetes\/Cardiovascular Risk (E Mayer-Davis and C Shay, Section Editors)

Beta Cell Function and the Nutritional State: Dietary Factors that Influence Insulin Secretion

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Hypoglycemia and Comorbidities in Type 2 Diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise